[Form 4] WEST PHARMACEUTICAL SERVICES INC Insider Trading Activity
Janet Brutschea Haugen, a director of West Pharmaceutical Services, Inc. (WST), reported transactions dated 09/30/2025. The Form 4 discloses a disposition of 1,319.348 shares of Common Stock and the acquisition of 48 Phantom Stock Units on the same date. The filing shows 162.161 shares reported as beneficially owned following the reported derivative transaction. Footnotes state the 1,071 restricted stock units and dividend equivalents underlying part of the position will vest in full at the next annual shareholder meeting and be distributable under the Deferred Compensation Plan for Outside Directors, and that phantom stock units are settled by delivery of shares upon the reporting person’s termination as a director. The form is signed by an agent on behalf of Ms. Haugen on 10/02/2025.
Janet Brutschea Haugen, una direttrice di West Pharmaceutical Services, Inc. (WST), ha riportato operazioni datate 30/09/2025. Il modulo 4 rivela una cessione di 1.319,348 azioni ordinarie e l'acquisizione di 48 Unità di Azioni Fantasma nella stessa data. La documentazione riporta 162.161 azioni detenute beneficiariamente a seguito della transazione derivata riportata. Note a piè di pagina indicano che le 1.071 unità di azioni vincolate e gli equivalenti di dividendo che fanno parte della posizione matureranno integralmente al prossimo incontro annuale degli azionisti e saranno distribuibili ai sensi del Piano di compensazione differita per i direttori esterni, e che le unità di azioni fantasma verranno regolate mediante consegna di azioni al termine della carica di direttore della persona riportante. Il modulo è firmato da un agente per conto della signora Haugen il 02/10/2025.
Janet Brutschea Haugen, una directora de West Pharmaceutical Services, Inc. (WST), informó transacciones con fecha 30/09/2025. El Formulario 4 divulga la venta de 1.319,348 acciones comunes y la adquisición de 48 Unidades de Acciones Fantasma en la misma fecha. La documentación señala 162.161 acciones reportadas como poseídas de forma beneficiosa tras la transacción derivada reportada. Las notas al pie señalan que las 1.071 unidades de acciones restringidas y los equivalentes de dividendos subyacentes a parte de la posición vencerán por completo en la próxima asamblea anual de accionistas y serán distribuidos conforme al Plan de Compensación Diferida para Directores Exteriores, y que las unidades de acciones fantasma se liquidarán mediante la entrega de acciones al finalizar la función de directora de la persona reportante. El formulario está firmado por un agente en nombre de la Sra. Haugen el 02/10/2025.
Janet Brutschea Haugen은 West Pharmaceutical Services, Inc. (WST)의 이사로, 2025년 9월 30일자 거래를 보고했습니다. Form 4는 같은 날짜에 1,319.348주 일반주 처분과 48 팬텀스톡 유닛 취득을 공시합니다. 제출서는 파생거래 이후 보유 이익 주식 162.161주로 보고되었다고 명시합니다. 각주에 따르면 포지션의 일부를 구성하는 1,071개의 제한주식(RSU)와 배당수익이 다음 연차 주주총회에서 전액 행사되며 외부 이사를 위한 연금후생계획(Deferred Compensation Plan for Outside Directors)에 따라 분배될 것이고, 보고자 이사가 이직할 때 팬텀스톡 유닛이 주식 인도로 해결됩니다. 양식은 2025년 10월 2일 Haugen 씨를 대신하여 대리인이 서명했습니다.
Janet Brutschea Haugen, une administratrice de West Pharmaceutical Services, Inc. (WST), a signalé des transactions datées du 30/09/2025. Le formulaire 4 divulgue une cession de 1.319,348 actions ordinaires et l'acquisition de 48 unités d’actions fantômes à la même date. Le dépôt indique 162.161 actions détenues de manière bénéficiaire à la suite de la transaction dérivée signalée. Les notes de bas de page indiquent que les 1.071 unités d’actions restreintes et les équivalents de dividendes sous-jacents à une partie de la position se vestiront entièrement lors de la prochaine assemblée annuelle des actionnaires et seront distribuables en vertu du Plan de rémunération différée pour les administrateurs externes, et que les unités d’actions fantômes seront réglées par la remise d’actions à la cessation de la fonction de administrateur par la personne déclarant. Le formulaire est signé par un agent au nom de Mme Haugen le 02/10/2025.
Janet Brutschea Haugen, eine Direktorin von West Pharmaceutical Services, Inc. (WST), meldete Transaktionen vom 30.09.2025. Das Formular 4 offenbart eine Veräußerung von 1.319,348 Stammaktien und den Erwerb von 48 Phantomaktieneinheiten am selben Datum. Die Einreichung zeigt 162.161 Aktien als wirtschaftlich berechtigt nach der berichteten derivativen Transaktion. Fußnoten besagen, dass die 1.071 Restricted Stock Units und die zugehörigen Dividendenäquivalente, die der Position zugrunde liegen, bei der nächsten ordentlichen Hauptversammlung vollständig vesten und gemäß dem Deferred Compensation Plan for Outside Directors auszahlbar sein werden, und dass Phantomstock-Einheiten durch Lieferung von Aktien bei Beendigung der Direktorenfunktion der meldenden Person abgewickelt werden. Das Formular ist von einem Bevollmächtigten im Namen von Frau Haugen am 02.10.2025 unterzeichnet worden.
جانيت برشتشيا هاوغان، مديرة في West Pharmaceutical Services, Inc. (WST)، أبلغت عن معاملات بتاريخ 30/09/2025. يفصح النموذج 4 عن تصرف في 1,319.348 سهمًا من الأسهم العادية وعمليات شراء 48 وحدة أسهم خيالية في نفس التاريخ. تشير الوثيقة إلى أن 162.161 سهمًا مُبلَّغ عنها كمالكة مفيدة بعد المعاملة المشتبهة. توضح الحواشي أن 1,071 وحدة أسهم مقيدة والبدلات الموزعة المقترنة بمركز داخل جزء من الوضع ستكتسب بالكامل في الاجتماع السنوي المقبل للمساهمين وتكون قابلة للإيداع وفقًا لخطة التعويض المؤجل للمخرجين، وأن وحدات الأسهم الخيالية يتم settles by تسوية عبر تسليم الأسهم عند إنهاء التقرير للشخص كمدير. تم توقيع النموذج من قبل وكيل نيابة عن السيدة هاوغان في 02/10/2025.
Janet Brutschea Haugen，West Pharmaceutical Services, Inc.（WST）的董事，报告了日期为 2025-09-30 的交易。 Form 4 披露在同一天处置 1,319.348 股普通股，并取得 48 股幻影股票单位。该申报显示在所述衍生交易后，拥有受益所有权的股份为 162.161 股。脚注指出，构成该头寸部分的 1,071 个受限股票单位及其股息等额部分将在下一次年度股东大会前全部归属，并将依据外部董事Deferred Compensation Plan进行分配；幻影股票单位到期时将以交付股票方式清算。该表格于 2025-10-02 由代表 Haugen 女士的代理人签署。
- Director compensation tied to alignment: Restricted stock units and phantom units indicate continued alignment of Ms. Haugen’s incentives with shareholders.
- Clear vesting and settlement terms disclosed: Footnotes specify vesting at the next annual meeting for RSUs and settlement-on-termination for phantom units.
- None.
Insights
TL;DR: Routine director compensation movements: a reported disposition and grant tied to deferred compensation and phantom units.
The Form 4 shows a disposition of 1,319.348 common shares and an award of 48 phantom stock units on 09/30/2025. Footnotes clarify that 1,071 restricted stock units plus dividend equivalents will vest at the next annual meeting and are payable under the outside directors' deferred compensation plan, and that phantom units convert to shares upon termination. These items are consistent with customary director compensation mechanics rather than an operational signal about the company. No cash proceeds, sale price, or reason for the disposition beyond the codes provided are included in the filing.
TL;DR: Director-level equity changes reflect standard deferred compensation and termination-settled phantom units.
The filing documents compensatory equity arrangements: restricted stock units that vest at the next annual meeting and phantom stock units that settle in shares upon director termination. Such structures are typical for outside directors to defer income and align incentives with shareholders. The Form 4 does not provide context such as total outstanding director holdings before these entries beyond the post-transaction beneficial ownership figure of 162.161 shares, so governance implications are limited to confirming these standard arrangements exist for Ms. Haugen.
Janet Brutschea Haugen, una direttrice di West Pharmaceutical Services, Inc. (WST), ha riportato operazioni datate 30/09/2025. Il modulo 4 rivela una cessione di 1.319,348 azioni ordinarie e l'acquisizione di 48 Unità di Azioni Fantasma nella stessa data. La documentazione riporta 162.161 azioni detenute beneficiariamente a seguito della transazione derivata riportata. Note a piè di pagina indicano che le 1.071 unità di azioni vincolate e gli equivalenti di dividendo che fanno parte della posizione matureranno integralmente al prossimo incontro annuale degli azionisti e saranno distribuibili ai sensi del Piano di compensazione differita per i direttori esterni, e che le unità di azioni fantasma verranno regolate mediante consegna di azioni al termine della carica di direttore della persona riportante. Il modulo è firmato da un agente per conto della signora Haugen il 02/10/2025.
Janet Brutschea Haugen, una directora de West Pharmaceutical Services, Inc. (WST), informó transacciones con fecha 30/09/2025. El Formulario 4 divulga la venta de 1.319,348 acciones comunes y la adquisición de 48 Unidades de Acciones Fantasma en la misma fecha. La documentación señala 162.161 acciones reportadas como poseídas de forma beneficiosa tras la transacción derivada reportada. Las notas al pie señalan que las 1.071 unidades de acciones restringidas y los equivalentes de dividendos subyacentes a parte de la posición vencerán por completo en la próxima asamblea anual de accionistas y serán distribuidos conforme al Plan de Compensación Diferida para Directores Exteriores, y que las unidades de acciones fantasma se liquidarán mediante la entrega de acciones al finalizar la función de directora de la persona reportante. El formulario está firmado por un agente en nombre de la Sra. Haugen el 02/10/2025.
Janet Brutschea Haugen은 West Pharmaceutical Services, Inc. (WST)의 이사로, 2025년 9월 30일자 거래를 보고했습니다. Form 4는 같은 날짜에 1,319.348주 일반주 처분과 48 팬텀스톡 유닛 취득을 공시합니다. 제출서는 파생거래 이후 보유 이익 주식 162.161주로 보고되었다고 명시합니다. 각주에 따르면 포지션의 일부를 구성하는 1,071개의 제한주식(RSU)와 배당수익이 다음 연차 주주총회에서 전액 행사되며 외부 이사를 위한 연금후생계획(Deferred Compensation Plan for Outside Directors)에 따라 분배될 것이고, 보고자 이사가 이직할 때 팬텀스톡 유닛이 주식 인도로 해결됩니다. 양식은 2025년 10월 2일 Haugen 씨를 대신하여 대리인이 서명했습니다.
Janet Brutschea Haugen, une administratrice de West Pharmaceutical Services, Inc. (WST), a signalé des transactions datées du 30/09/2025. Le formulaire 4 divulgue une cession de 1.319,348 actions ordinaires et l'acquisition de 48 unités d’actions fantômes à la même date. Le dépôt indique 162.161 actions détenues de manière bénéficiaire à la suite de la transaction dérivée signalée. Les notes de bas de page indiquent que les 1.071 unités d’actions restreintes et les équivalents de dividendes sous-jacents à une partie de la position se vestiront entièrement lors de la prochaine assemblée annuelle des actionnaires et seront distribuables en vertu du Plan de rémunération différée pour les administrateurs externes, et que les unités d’actions fantômes seront réglées par la remise d’actions à la cessation de la fonction de administrateur par la personne déclarant. Le formulaire est signé par un agent au nom de Mme Haugen le 02/10/2025.
Janet Brutschea Haugen, eine Direktorin von West Pharmaceutical Services, Inc. (WST), meldete Transaktionen vom 30.09.2025. Das Formular 4 offenbart eine Veräußerung von 1.319,348 Stammaktien und den Erwerb von 48 Phantomaktieneinheiten am selben Datum. Die Einreichung zeigt 162.161 Aktien als wirtschaftlich berechtigt nach der berichteten derivativen Transaktion. Fußnoten besagen, dass die 1.071 Restricted Stock Units und die zugehörigen Dividendenäquivalente, die der Position zugrunde liegen, bei der nächsten ordentlichen Hauptversammlung vollständig vesten und gemäß dem Deferred Compensation Plan for Outside Directors auszahlbar sein werden, und dass Phantomstock-Einheiten durch Lieferung von Aktien bei Beendigung der Direktorenfunktion der meldenden Person abgewickelt werden. Das Formular ist von einem Bevollmächtigten im Namen von Frau Haugen am 02.10.2025 unterzeichnet worden.
FAQ
What transactions did Janet Haugen report on Form 4 for WST?
How many shares did Janet Haugen beneficially own after the reported transactions?
What do the footnotes say about the restricted stock units?
When do the phantom stock units settle into shares?
Who signed the Form 4 and when was it signed?
